The SLAS Europe 2021 Digital Conference and Exhibition Programme will feature four important tracks focused on emerging biology, technology, discovery and careers in business and technology. Each track will feature sessions packed with the latest research on emerging topics as well as sessions focused on how to excel at building and succeeding in a career within the life sciences and biotech industries.
Additional programming information will be updated as soon as it becomes available.
Giulio Superti-Furga, Ph.D.
Medical University of Vienna
Johannes Grillari, Ph.D.
Ludwig Boltzmann Institute for Experimental and Clinical Traumatology
Georg Winter, Ph.D.
Research Center for Molecular Medicine of the Austrian Academy of Sciences
The track will focus on emerging targets and mechanisms including protein degradation, non-coding RNAs and stabilising PPIs. The therapeutic exploitation of intrinsic cellular functions including proteolysis pathways, autophagy and lysosomal degradation mechanisms will be explored. Leading experts in disease biology will present new strategies for identifying, investigating and validating challenging target mechanisms in case studies. Sessions will cover the process of translating biological insight into tractable assays, efficient tool compounds and biologicals, and methods for generating attractive starting points for drug discovery programmes.
The technology track covers recent technological innovations which promise to significantly enhance our understanding of disease-related mechanisms and eventually lead to fundamental improvements in the practice of drug discovery. The session on super-resolution microscopy will explore its emergence from basic research applications towards exciting new applications in industrial scale screening of biological events at unparalleled sub-cellular scales. The real world application of artificial intelligence methods in target identification and therapeutic discovery will be presented by key leaders in the field from pharma and biotech. The session on fragment screening will focus on library design and compound elaboration, as well as the increased use of information rich endpoints including high throughput X-ray crystallography.
In the Discovery track, new approaches to identifying attractive hits, confirming target engagement, progressing leads and selecting disease relevant candidates for new and established targets will be illustrated in detailed case studies. A session on precision medicine will cover quantitative, high-throughput approaches for using primary patient material, cellular models and complex tissues and how such patient insights can drive translation between disease insight and clinical application. Finally, innovative technologies for monitoring target engagement as well as downstream biological consequences will be showcased and their impact on increasing understanding of molecular selectivity and mode of action explored.
Thanks for your interest. This track will be offered as a standalone event — the Career & Business Showcase — later this year. In the meantime, take a look at our Job Board, CONNECTED online networking platform and Mentor Match, and upcoming awards and grants opportunities from SLAS.